Does Rallies show Form 4 insider transactions for PRVA?

Yes. Rallies tracks PRVA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PRVA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PRVA. It does not provide personalized investment advice.

PRVA (Privia Health Group, Inc. Common Stock) Stock Analysis - Insider Trades

Privia Health Group, Inc. Common Stock (PRVA) is a publicly traded Healthcare sector company. As of May 21, 2026, PRVA trades at $23.19 with a market cap of $2.99B and a P/E ratio of 128.57. PRVA moved -0.43% today. Year to date, PRVA is -3.98%; over the trailing twelve months it is -5.46%. Its 52-week range spans $16.47 to $26.51. Analyst consensus is strong buy with an average price target of $31.33. Rallies surfaces PRVA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PRVA stock inside the company?

Recent PRVA insider activity includes Mehrotra Parth sold 15.65K, Mehrotra Parth sold 105.44K, Mountcastle David sold 3.38K, Mountcastle David sold 1.21K, and Morris Matthew Shawn sold 1.02K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PRVA Key Metrics

Key financial metrics for PRVA
Metric	Value
Price	$23.19
Market Cap	$2.99B
P/E Ratio	128.57
EPS	$0.18
Dividend Yield	0.00%
52-Week High	$26.51
52-Week Low	$16.47
Volume	440.41K
Avg Volume	0
Revenue (TTM)	$2.25B
Net Income	$27.39M
Gross Margin	0.00%

Recent PRVA Insider Trades

Mehrotra Parth sold 15.65K (~$354.25K) on May 12, 2026.
Mehrotra Parth sold 105.44K (~$2.38M) on May 11, 2026.
Mountcastle David sold 3.38K (~$76.50K) on May 11, 2026.
Mountcastle David sold 1.21K (~$30.15K) on May 4, 2026.
Morris Matthew Shawn sold 1.02K (~$25.38K) on May 4, 2026.

Latest PRVA News

Privia Health Q1 Revenue Jumps 25.8% to $603.8 M with EBITDA Up 36.3% — May 7, 2026
Privia Health Q1 Revenue Seen at $580.65M, EPS $0.08; Full-Year Forecast Upgraded — May 6, 2026
Privia Health Earns 2026 HFMA MAP Award, Ninth Win in Ten Years — Mar 24, 2026
Analysts Project 25.5% Upside for Privia Health as PPI Surge Weighs on Shares — Feb 27, 2026
Privia Health Q4 Collections Rise 9.6% to $868.7M, EBITDA Jumps 26.4% — Feb 27, 2026

PRVA Analyst Consensus

15 analysts cover PRVA: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.33.

Common questions about PRVA

Who is trading PRVA stock inside the company?: Recent PRVA insider activity includes Mehrotra Parth sold 15.65K, Mehrotra Parth sold 105.44K, Mountcastle David sold 3.38K, Mountcastle David sold 1.21K, and Morris Matthew Shawn sold 1.02K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PRVA?: Yes. Rallies tracks PRVA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PRVA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PRVA. It does not provide personalized investment advice.